What is Iantrek?
Founded by renowned ophthalmic innovator Dr. Sean Ianchulev, Iantrek is a specialized medical technology firm dedicated to pioneering bio-interventional and micro-interventional products. The company's sophisticated portfolio, which includes proprietary solutions such as AlloSert Uveo, AlloFlo Uveo, CanaloFlo, and C.Rex, is engineered to address the complex challenges associated with glaucoma treatment. By focusing on minimally invasive techniques, Iantrek is redefining the standard of care in ophthalmology, providing surgeons with the precision tools necessary to improve long-term patient prognosis and surgical efficiency in a rapidly evolving healthcare market.
How much funding has Iantrek raised?
Iantrek has raised a total of $135M across 5 funding rounds:
Series A
$5.2M
Series B
$23M
Series C
$42M
Private Equity
$34.7M
Debt
$30M
Series A (2020): $5.2M, investors not publicly disclosed
Series B (2022): $23M led by Visionary Ventures and Sectoral Asset Management
Series C (2025): $42M supported by US Venture Partners, Sectoral Asset Management, Visionary Ventures, and aMoon
Private Equity (2025): $34.7M, investors not publicly disclosed
Debt (2026): $30M backed by Trinity Capital
Key Investors in Iantrek
US Venture Partners
A prominent Silicon Valley venture capital firm specializing in early-stage investments across cybersecurity, enterprise software, and healthcare sectors.
Sectoral Asset Management
An investment advisor specializing in managing global healthcare equities, with a strong track record in biotech and life sciences.
Visionary Ventures
An Orange County-based VC firm that leverages partnerships with industry experts and KOLs to support promising ophthalmology and life sciences startups.
What's next for Iantrek?
With the infusion of this recent capital, Iantrek is well-positioned to accelerate its commercialization efforts and expand its clinical footprint. The company's strategic roadmap likely involves scaling the manufacturing of its core micro-interventional platforms and deepening its engagement with global healthcare providers. As Iantrek transitions into a more mature phase of its lifecycle, the focus will shift toward broader market penetration and the potential development of next-generation surgical technologies. This financial momentum provides the necessary runway to sustain long-term research and development, ensuring that Iantrek remains at the cutting edge of ophthalmic innovation while addressing the significant unmet medical needs of the global glaucoma patient population.
See full Iantrek company page
